CLEARONE INC 8-K

What Happened

• On July 1, 2026 ClearOne, Inc. (Nasdaq: CLRO) entered into an Agreement and Plan of Merger to acquire Cortigent, Inc. via a merger of a ClearOne subsidiary into Cortigent. As consideration, Vivani Medical, Inc. (the seller) will receive 12,500,000 shares of ClearOne common stock. ClearOne announced the agreement in a press release on July 2, 2026.

Key Details

• Consideration: 12,500,000 shares of ClearOne common stock issued to Vivani (no fractional shares); shares subject to registration rights and lock-ups (50% locked 1 year, 50% locked 2 years).
• Financing: ClearOne will file a Form S‑1 to raise $10.0M–$15.0M concurrently with seeking stockholder approval; planned as units (shares plus warrants).
• Governance & management: Post-closing board will have five directors (Adam Mendelsohn as Chair; Eric Robinson to chair the audit committee). Post-closing officers listed: Jonathan Adams (President & CEO), Ed Sedo (CFO & Principal Accounting Officer), Rachel Evans (Corporate Secretary).
• Other terms: up to 1,400,000 stock options and up to 855,000 shares may be issued to certain individuals/consultants; 12‑month equity issuance moratorium after closing with limited exceptions; closing subject to shareholder approvals, completion of the financing, Nasdaq listing continuation, effectiveness of the S‑1, and other customary conditions. Agreement may be terminated if not closed within 180 days (with possible extensions).

Why It Matters

• This is a transformational deal that will increase ClearOne’s share count immediately (12.5M shares issued) and could further dilute holders if the planned $10M–$15M financing proceeds. The financing is a closing condition, so the transaction depends on successful capital raising and shareholder approvals.
• The agreement sets the post‑closing board and named officers, outlines advisor/employee equity grants, and imposes lock-ups that limit Vivani’s ability to sell the Consideration Shares in the near term—factors investors should watch when assessing governance and near‑term supply of shares.